Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy: Molecular Therapy - Oncolytics

Frontiers CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer

PDF) Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Frontiers CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer

Cancers, Free Full-Text

Frontiers Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy

Cellular Therapy in NSCLC: Between Myth and Reality

CRISPR in cancer biology and therapy

Frontiers Emerging Strategies in TCR-Engineered T Cells

News: PD-1 Targeted Cancer Immunotherapy Meets CRISPR - CRISPR Medicine

CAR-T cell therapy: current limitations and potential strategies

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Frontiers Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect

Frontiers Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?